Vyne Therapeutics Inc Financials

VYNE

Source SEC Filings (10-K/10-Q) Updated Jun 30, 2025 Currency USD FYE December

This page shows Vyne Therapeutics Inc (VYNE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Key Financial Metrics

Revenue

$501K

YoY+18.2%

5Y CAGR+2.5%

Vyne Therapeutics Inc generated $501K in revenue in fiscal year 2024. This represents an increase of 18.2% from the prior year.

EBITDA

-$43.6M

YoY-49.1%

Vyne Therapeutics Inc's EBITDA was -$43.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 49.1% from the prior year.

Free Cash Flow

-$34.1M

YoY-34.5%

Vyne Therapeutics Inc generated -$34.1M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 34.5% from the prior year.

Net Income

-$39.8M

YoY-40.0%

Vyne Therapeutics Inc reported -$39.8M in net income in fiscal year 2024. This represents a decrease of 40.0% from the prior year.

EPS (Diluted)

$-0.93

YoY+66.5%

Vyne Therapeutics Inc earned $-0.93 per diluted share (EPS) in fiscal year 2024. This represents an increase of 66.5% from the prior year.

Cash & Debt

$19.9M

YoY-34.9%

5Y CAGR-14.6%

Vyne Therapeutics Inc held $19.9M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

15M

YoY+5.2%

5Y CAGR+10.2%

Vyne Therapeutics Inc had 15M shares outstanding in fiscal year 2024. This represents an increase of 5.2% from the prior year.

Gross Margin

N/A

Operating Margin

-8710.0%

YoY-1809.5pp

5Y CAGR+12931.8pp

Vyne Therapeutics Inc's operating margin was -8710.0% in fiscal year 2024, reflecting core business profitability. This is down 1809.5 percentage points from the prior year.

Net Margin

-7950.9%

YoY-1240.5pp

5Y CAGR+13534.0pp

Vyne Therapeutics Inc's net profit margin was -7950.9% in fiscal year 2024, showing the share of revenue converted to profit. This is down 1240.5 percentage points from the prior year.

Return on Equity

N/A

R&D Spending

$30.9M

YoY+89.8%

5Y CAGR-9.6%

Vyne Therapeutics Inc invested $30.9M in research and development in fiscal year 2024. This represents an increase of 89.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$117K

5Y CAGR-35.6%

Vyne Therapeutics Inc invested $117K in capex in fiscal year 2024, funding long-term assets and infrastructure.

VYNE Income Statement

Metric	FY24	FY24	FY23	FY22	FY21	FY20
Revenue	$501K+18.2%	$424K-11.1%	$477K-48.8%	$931K-95.6%	$21.0M+4638.8%	$443K
Cost of Revenue	N/A	N/A	N/A	$3.3M+140.5%	$1.4M	$0
Gross Profit	N/A	N/A	N/A	-$2.4M-112.3%	$19.6M+4324.6%	$443K
R&D Expenses	$30.9M+89.8%	$16.3M-11.3%	$18.4M-5.9%	$19.5M-55.1%	$43.5M-15.0%	$51.2M
SG&A Expenses	$13.2M-1.4%	$13.4M-18.4%	$16.4M-19.3%	$20.3M-77.3%	$89.5M+98.5%	$45.1M
Operating Income	-$43.6M-49.1%	-$29.3M+14.7%	-$34.3M+11.9%	-$38.9M+84.6%	-$252.5M-163.4%	-$95.9M
Interest Expense	N/A	N/A	$0-100.0%	$5.6M+27.8%	$4.4M+376.7%	$921K
Income Tax	$4K	$0-100.0%	$13K+102.9%	-$448K-73.6%	-$258K-46.6%	-$176K
Net Income	-$39.8M-40.0%	-$28.5M-22.6%	-$23.2M+68.3%	-$73.3M+71.3%	-$255.6M-168.5%	-$95.2M
EPS (Diluted)	$-0.93+66.5%	$-2.78+61.8%	$-7.28+71.6%	$-25.64-425.4%	$7.88	N/A

Metric	Q2'25	Q1'25	Q2'25	Q3'24	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$69K-65.8%	$202K	N/A	$121K-38.9%	$198K+102.0%	$98K	N/A	$114K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$4.9M-20.3%	$6.1M	N/A	$10.2M+40.3%	$7.3M+97.0%	$3.7M	N/A	$3.3M
SG&A Expenses	$2.7M-16.6%	$3.3M	N/A	$3.0M-9.9%	$3.3M-12.8%	$3.8M	N/A	$3.0M
Operating Income	-$7.5M+18.0%	-$9.2M	N/A	-$13.1M-25.9%	-$10.4M-40.9%	-$7.4M	N/A	-$6.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	$0	N/A	$0	$0	$0	N/A	$0
Net Income	-$5.8M+33.2%	-$8.6M	N/A	-$12.2M-29.2%	-$9.4M-50.5%	-$6.2M	N/A	-$6.6M
EPS (Diluted)	$-0.13+35.0%	$-0.20	N/A	$-0.29-31.8%	$-0.22-46.7%	$-0.15	N/A	$-2.01

VYNE Balance Sheet

Metric	FY24	FY24	FY23	FY22	FY21	FY20
Total Assets	$66.9M-31.5%	$97.7M+139.7%	$40.8M-39.2%	$67.0M-28.5%	$93.7M+15.5%	$81.2M
Current Assets	$64.4M-32.9%	$96.0M+150.7%	$38.3M-39.4%	$63.2M-27.6%	$87.3M+14.2%	$76.4M
Cash & Equivalents	$19.9M-34.9%	$30.6M-0.9%	$30.9M-26.8%	$42.3M-26.6%	$57.6M+31.5%	$43.8M
Inventory	N/A	N/A	N/A	$7.3M-1.5%	$7.4M+446.0%	$1.4M
Accounts Receivable	N/A	N/A	$173K-97.7%	$7.6M-52.1%	$15.8M+11617.8%	$135K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$14.8M+65.6%	$8.9M-4.2%	$9.3M-49.2%	$18.4M-67.3%	$56.2M-11.5%	$63.6M
Current Liabilities	$14.8M+96.6%	$7.5M-19.3%	$9.3M-49.2%	$18.4M-15.4%	$21.8M-25.8%	$29.3M
Long-Term Debt	$0	$0	$0	$0-100.0%	$33.2M+1.4%	$32.7M
Total Equity	$52.1M-41.3%	$88.7M+184.4%	$31.2M-35.8%	$48.6M+29.7%	$37.5M+113.3%	$17.6M
Retained Earnings	-$731.2M-5.8%	-$691.3M-4.3%	-$662.7M-3.6%	-$639.5M-13.0%	-$566.2M-82.3%	-$310.6M

Metric	Q2'25	Q1'25	Q2'25	Q3'24	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$44.7M-20.7%	$56.4M-15.7%	$66.9M-12.2%	$76.2M-12.1%	$86.6M-5.5%	$91.7M-6.2%	$97.7M+407.0%	$19.3M
Current Assets	$44.3M-19.2%	$54.9M-14.8%	$64.4M-12.4%	$73.5M-12.2%	$83.8M-7.1%	$90.2M-6.0%	$96.0M+448.0%	$17.5M
Cash & Equivalents	$22.0M-21.8%	$28.2M+41.6%	$19.9M+22.5%	$16.3M-45.0%	$29.6M+55.3%	$19.1M-37.7%	$30.6M+98.2%	$15.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$250K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$5.8M-52.5%	$12.3M-17.1%	$14.8M+17.0%	$12.7M+7.5%	$11.8M+41.8%	$8.3M-7.2%	$8.9M+15.3%	$7.8M
Current Liabilities	$5.8M-52.5%	$12.3M-17.1%	$14.8M+17.0%	$12.7M+7.7%	$11.8M+69.6%	$6.9M-8.1%	$7.5M+16.9%	$6.4M
Long-Term Debt	$0	$0	$0	$0	$0	$0	$0	$0
Total Equity	$38.9M-11.9%	$44.1M-15.3%	$52.1M-18.0%	$63.5M-15.1%	$74.9M-10.2%	$83.4M-6.0%	$88.7M+671.3%	$11.5M
Retained Earnings	-$745.5M-0.8%	-$739.8M-1.2%	-$731.2M-1.7%	-$719.1M-1.7%	-$707.0M-1.3%	-$697.6M-0.9%	-$691.3M-0.9%	-$685.1M

VYNE Cash Flow Statement

Metric	FY24	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$34.0M-34.1%	-$25.3M+13.2%	-$29.2M+48.2%	-$56.4M+58.9%	-$137.1M-86.8%	-$73.4M
Capital Expenditures	$117K	$0	N/A	$0-100.0%	$113K-89.3%	$1.1M
Free Cash Flow	-$34.1M-34.5%	-$25.3M	N/A	-$56.4M+58.9%	-$137.2M-84.3%	-$74.5M
Investing Cash Flow	$23.4M+140.7%	-$57.4M-466.1%	$15.7M+1425.5%	$1.0M-98.8%	$89.1M+112.8%	$41.9M
Financing Cash Flow	-$141K-100.2%	$82.4M+4884.5%	$1.7M-95.8%	$39.8M-35.6%	$61.8M+28.9%	$48.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'25	Q1'25	Q2'25	Q3'24	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	N/A	-$11.5M	N/A	N/A	N/A	-$8.0M	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	$19.8M	N/A	N/A	N/A	-$3.6M	N/A	N/A
Financing Cash Flow	N/A	-$87K	N/A	N/A	N/A	-$5K	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

VYNE Financial Ratios

Metric	FY24	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	-259.6%-353.0pp	93.4%-6.6pp	100.0%
Operating Margin	-8710.0%-1809.5pp	-6900.5%+289.3pp	-7189.7%-3010.3pp	-4179.5%-2976.5pp	-1203.0%+20438.8pp	-21641.8%
Net Margin	-7950.9%-1240.5pp	-6710.4%-1844.6pp	-4865.8%+3010.5pp	-7876.4%-6659.0pp	-1217.4%+20267.5pp	-21484.9%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-59.5%-30.4pp	-29.1%+27.8pp	-57.0%+52.4pp	-109.4%+163.3pp	-272.6%-155.4pp	-117.3%
Current Ratio	4.35-8.4	12.73+8.6	4.10+0.7	3.43-0.6	4.01+1.4	2.61
Debt-to-Equity	0.000.0	0.000.0	0.000.0	0.00-0.9	0.88-1.0	1.86
FCF Margin	-6804.2%-827.5pp	-5976.6%	N/A	-6054.5%-5400.9pp	-653.5%+16152.8pp	-16806.3%

Metric	Q2'25	Q1'25	Q2'25	Q3'24	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-10930.4%-6377.5pp	-4553.0%	N/A	-10819.0%-5568.5pp	-5250.5%+2280.1pp	-7530.6%	N/A	-5468.4%
Net Margin	-8340.6%-4077.7pp	-4262.9%	N/A	-10047.1%-5296.6pp	-4750.5%+1626.0pp	-6376.5%	N/A	-5775.4%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-12.9%+2.4pp	-15.3%	N/A	-16.0%-5.1pp	-10.9%-4.0pp	-6.8%	N/A	-34.2%
Current Ratio	7.60+3.1	4.47+0.1	4.35-1.5	5.81-1.3	7.13-5.9	13.02+0.3	12.73+10.0	2.72
Debt-to-Equity	0.000.0	0.000.0	0.000.0	0.000.0	0.000.0	0.000.0	0.000.0	0.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Financial Health Signals

Piotroski F-Score Weak

2/9

Financial strength trend (9 signals). 7-9 = strong, 0-3 = weak.

Earnings Quality Low Quality

0.85x

Operating cash flow vs net income. Above 1.0x = cash-backed earnings.

Similar Companies

Cyclerion Therapeutics Inc CYCN

$4.6M

Aprea Therapeutics, Inc. APRE

$4.1M

Galmed Pharmaceu GLMD

$4.0M

Turnstone Biologics Corp TSBX

$8.2M

Adial Pharmaceuticals Inc ADIL

$3.2M

Frequently Asked Questions

What is Vyne Therapeutics Inc's annual revenue?

Vyne Therapeutics Inc (VYNE) reported $501K in total revenue for fiscal year 2024. This represents a 18.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Vyne Therapeutics Inc's revenue growing?

Vyne Therapeutics Inc (VYNE) revenue grew by 18.2% year-over-year, from $424K to $501K in fiscal year 2024.

Is Vyne Therapeutics Inc profitable?

No, Vyne Therapeutics Inc (VYNE) reported a net income of -$39.8M in fiscal year 2024, with a net profit margin of -7950.9%.

What is Vyne Therapeutics Inc's earnings per share (EPS)?

Vyne Therapeutics Inc (VYNE) reported diluted earnings per share of $-0.93 for fiscal year 2024. This represents a 66.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Vyne Therapeutics Inc's EBITDA?

Vyne Therapeutics Inc (VYNE) had EBITDA of -$43.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Vyne Therapeutics Inc have?

As of fiscal year 2024, Vyne Therapeutics Inc (VYNE) had $19.9M in cash and equivalents against $0 in long-term debt.

What is Vyne Therapeutics Inc's operating margin?

Vyne Therapeutics Inc (VYNE) had an operating margin of -8710.0% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Vyne Therapeutics Inc's net profit margin?

Vyne Therapeutics Inc (VYNE) had a net profit margin of -7950.9% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Vyne Therapeutics Inc's free cash flow?

Vyne Therapeutics Inc (VYNE) generated -$34.1M in free cash flow during fiscal year 2024. This represents a -34.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Vyne Therapeutics Inc's operating cash flow?

Vyne Therapeutics Inc (VYNE) generated -$34.0M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Vyne Therapeutics Inc's total assets?

Vyne Therapeutics Inc (VYNE) had $66.9M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Vyne Therapeutics Inc's capital expenditures?

Vyne Therapeutics Inc (VYNE) invested $117K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Vyne Therapeutics Inc spend on research and development?

Vyne Therapeutics Inc (VYNE) invested $30.9M in research and development during fiscal year 2024.

How many shares does Vyne Therapeutics Inc have outstanding?

Vyne Therapeutics Inc (VYNE) had 15M shares outstanding as of fiscal year 2024.

What is Vyne Therapeutics Inc's current ratio?

Vyne Therapeutics Inc (VYNE) had a current ratio of 4.35 as of fiscal year 2024, which is generally considered healthy.

What is Vyne Therapeutics Inc's debt-to-equity ratio?

Vyne Therapeutics Inc (VYNE) had a debt-to-equity ratio of 0.00 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Vyne Therapeutics Inc's return on assets (ROA)?

Vyne Therapeutics Inc (VYNE) had a return on assets of -59.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Vyne Therapeutics Inc's cash runway?

Based on fiscal year 2024 data, Vyne Therapeutics Inc (VYNE) had $19.9M in cash against an annual operating cash burn of $34.0M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Vyne Therapeutics Inc's Piotroski F-Score?

Vyne Therapeutics Inc (VYNE) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals.

Are Vyne Therapeutics Inc's earnings high quality?

Vyne Therapeutics Inc (VYNE) has an earnings quality ratio of 0.85x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation.